Charles Schwab Investment Management Inc Cytom X Therapeutics, Inc. Transaction History
Charles Schwab Investment Management Inc
- $557 Billion
- Q2 2025
A detailed history of Charles Schwab Investment Management Inc transactions in Cytom X Therapeutics, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 88,570 shares of CTMX stock, worth $300,252. This represents 0.0% of its overall portfolio holdings.
Number of Shares
88,570
Previous 24,877
256.03%
Holding current value
$300,252
Previous $15,000
1240.0%
% of portfolio
0.0%
Previous 0.0%
Shares
25 transactions
Others Institutions Holding CTMX
# of Institutions
88Shares Held
123MCall Options Held
305KPut Options Held
121K-
Vr Adviser, LLC New York, NY14MShares$47.4 Million6.28% of portfolio
-
Tang Capital Management LLC San Diego, CA11.1MShares$37.5 Million1.5% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.38MShares$31.8 Million0.0% of portfolio
-
Orbimed Advisors LLC San Diego, CA8.46MShares$28.7 Million0.69% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct8.08MShares$27.4 Million0.04% of portfolio
About CytomX Therapeutics, Inc.
- Ticker CTMX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 65,950,200
- Market Cap $224M
- Description
- CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...